9/25/2013

Alliqua, formerly known as AquaMed Technologies, is transitioning from contract manufacturing to developing wound-care products and technologies. The FDA has already approved two hydrogels by Alliqua, and the company plans to offer up to 10 complementary products, says CEO David Johnson, the former head of Bristol-Myers Squibb wound-care division ConvaTec.

Related Summaries